Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galera Therapeutics, Inc. (GRTXD : OTC)

• Company Description    Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which is designed to rapidly convert superoxide to hydrogen peroxide. Galera Therapeutics, Inc. is headquartered in Malvern, PA. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $17.50 Daily Weekly Monthly 20 Day Moving Average: 560 shares Shares Outstanding: 1.04 (millions) Market Capitalization: $18.20 (millions) Beta: 2.60 52 Week High: $23.80 52 Week Low: $3.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.69% -2.41% 12 Week -12.50% -14.90% Year To Date 297.73% 267.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 LINDENWOOD DRIVE SUITE 225 - MALVERN,PA 19355 USA ph: 610-725-1500 fax: - jsussman@galeratx.com http://www.galeratx.com

• General Corporate Information    Officers J. Mel Sorensen - Chief Executive Officer and President Joel Sussman - Principal Financial Officer Lawrence Alleva - Director Kevin Lokay - Director Michael Friedman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36338D207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 1.04 Most Recent Split Date: 7.00 (0.01:1) Beta: 2.60 Market Capitalization: $18.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 0.14 PEG Ratio: - Price Ratios Price/Book: 9.07 Price/Cash Flow: 0.10 Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -101.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -85.83 12/31/25 - -57.00 ROA 06/30/26 - - 03/31/26 - 1,028.40 12/31/25 - 969.07 Current Ratio 06/30/26 - - 03/31/26 - 5.31 12/31/25 - 11.00 Quick Ratio 06/30/26 - - 03/31/26 - 5.31 12/31/25 - 11.00 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.93 12/31/25 - 10.53 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©